An optimized peptide vaccine strategy capable of inducing multivalent CD8⁺ T cell responses with potent antitumor effects.

ABSTRACT: Therapeutic cancer vaccines are an attractive alternative to conventional therapies for treating malignant tumors, and successful tumor eradication depends primarily on obtaining high numbers of long-lasting tumor-reactive CD8⁺ T cells. Dendritic cell (DC)-based vaccines constitute a promising approach for treating cancer, but in most instances low immune responses and suboptimal therapeutic effects are achieved indicating that further optimization is required. We describe here a novel vaccination strategy with peptide-loaded DCs followed by a mixture of synthetic peptides, polyinosine-polycytidylic acid (poly-IC) and anti-CD40 antibodies (TriVax) for improving the immunogenicity and therapeutic efficacy of DC-based vaccines in a melanoma mouse model. TriVax immunization 7-12 d

SUBMITTER: Cho HI 

PROVIDER: S-EPMC4589052 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature